抗血管内皮生长因子(VEGF)治疗与视网膜下纤维化研究进展  

Anti-VEGF therapy and subretinal fibrosis

作　　者：吕亚男[1] 宫媛媛[1] 

机构地区：[1]上海交通大学附属第一人民医院眼科,上海市200080

出　　处：《眼科新进展》2017年第6期583-586,共4页Recent Advances in Ophthalmology

基　　金：国家自然科学基金项目(编号:81300774);上海市自然科学基金项目(编号:12ZR1424500);上海市眼底病重点实验室开放课题基金项目(编号:07Z22911)~~

摘　　要：视网膜下纤维化是导致年龄相关性黄斑病变视力丧失的原因之一,抗血管内皮生长因子治疗是目前对于湿性年龄相关性黄斑变性标准治疗方案。本文主要探讨视网膜纤维化的影响因素,抗血管内皮生长因子治疗与视网膜纤维化的关系以及抗视网膜下纤维化的研究进展。Subretinal fibrosis contributes to the loss of vision associated with age- related macular degeneration. Anti-vascular endothelial growth factor therapy is the cur- rent standard treatment for exudative age-related macular degeneration. In this review, many risk factors of subretinal fibrosis are discussed, the relationship between anti-vas- cular endothelial growth factor therapy and subretinal fibrosis, some potential novel therapeutic methods to suppresses subretinal fibrosis are also revealed.

关 键 词：视网膜下纤维化 年龄相关性黄斑变性 抗血管内皮生长因子 

分 类 号：R774[医药卫生—眼科]